ACEIs and ARBs Treatment in Diabetic Patients -Drug Interactions and Adverse Drug Effects
NCT ID: NCT00437775
Last Updated: 2007-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2007-01-31
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography
NCT01071642
High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy
NCT00212901
Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination
NCT04143412
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
NCT01500590
African American Study of Kidney Disease and Hypertension ABPM Pilot Study
NCT00582777
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During hospitalization, data regarding the clinical history,chronic diseases and drugs were collected from the medical files. Blood tests results were recorded during hospitalization .The patients were asked about adverse drug effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
DEFINED_POPULATION
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assaf-Harofeh Medical Center
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahuva Golik, Assoc. Prof.
Role: STUDY_DIRECTOR
Sackler School of Medicine, Tel-Aviv University
Alina Alperovich, B.Pharm
Role: PRINCIPAL_INVESTIGATOR
Assaf-Harofeh Medical Center
Lila Akivison, MSc.Pharm
Role: STUDY_CHAIR
Assaf-Harofeh Medical Center
Sofia Berkovitch, MSc. Pharm
Role: STUDY_CHAIR
Assaf-Harofeh Medical Center
Gabby Elbaz, MD
Role: STUDY_CHAIR
Assaf- Hrofech Medical Senter
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assaf Harofeh Medical Center
Ẕerifin, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care. 2006 Oct;29(10):2210-7. doi: 10.2337/dc06-0570.
Andros V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm. 2006 May;12(4):303-9. doi: 10.18553/jmcp.2006.12.4.303.
Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens. 2006 Jan;24(1):11-25. doi: 10.1097/01.hjh.0000191244.91314.9d.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
167/06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.